The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Åke Borg

Åke Borg

Principal investigator

Åke Borg

Detecting EGFR alterations in clinical specimens-pitfalls and necessities.

Author

  • Sofi Isaksson
  • Pär-Ola Bendahl
  • Annette Salomonsson
  • Mats Jönsson
  • Monica Haglund
  • Alexander Gaber
  • Karin Jirström
  • Per Jönsson
  • Åke Borg
  • Leif Johansson
  • Johan Staaf
  • Maria Planck
Show all

Summary, in English

We investigated the epidermal growth factor receptor (EGFR) status in early stage lung cancer in Southern Sweden, a population for which there are no previous reports on the EGFR mutation frequency. Three hundred fifty small cell lung cancers, adenocarcinomas (AC), squamous cell carcinomas (SqCC), and large cell carcinomas were analyzed using a combination of techniques for the analysis of protein expression, gene copy numbers, and mutations. Immunohistochemical (IHC) staining with antibodies for the EGFR mutations L858R and del E746-A750 revealed intratumoral heterogeneity and several discrepant cases when compared to mutation-specific polymerase chain reaction (PCR)-based analysis. The frequencies of these two mutations, when considering IHC staining with mutation-specific antibodies in a cohort of 298 cases and subsequent confirmation by PCR, were 10 % in AC and <2 % in SqCC. Furthermore, screening by sequencing of EGFR in a cohort of 52 lung AC and squamous carcinomas demonstrated a more diverse mutation spectrum, not covered by the mutation-specific antibodies. High expression of total EGFR protein was correlated to high gene copy numbers but did not reflect the mutational status of the tumors. We believe that the mutation spectra in a Southern Swedish population is too diverse to be covered by the mutation-specific antibodies, and we also raise some other issues regarding the use of the mutation-specific antibodies, for example concerning heterogeneous expression of the mutated protein, optimal antibody dilution, and discrepancies between staining results and PCR.

Department/s

  • Breastcancer-genetics
  • Tumor microenvironment
  • Thoracic Surgery
  • Research Group Lung Cancer
  • BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation

Publishing year

2013

Language

English

Pages

755-764

Publication/Series

Virchows Archiv: an international journal of pathology

Volume

463

Issue

6

Document type

Journal article

Publisher

Springer

Topic

  • Cancer and Oncology

Status

Published

Research group

  • Research Group Lung Cancer

ISBN/ISSN/Other

  • ISSN: 1432-2307